EUCTR2018-000168-27-IT进行中（未招募）1 期
Open-label, phase IIIb study of dabrafenib in COMBInation with trametinib in the Adjuvant treatment of stage III BRAF V600 mutation-positive melanoma after complete resection to evaluate the impact on pyrexia related outcomes of an adapted pyrexia AE-management algorithm (Plus) - COMBI-APlus
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 552
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Completely resected histologically confirmed cutaneous melanoma stage IIIA (LN metastasis >1 mm), IIIB, IIIC, IIID [AJCC (ed 8)]
- •V600E/K mutation positive using a validated local test
- •Subjects presenting with initial resectable lymph node recurrence after a diagnosis of Stage I or II melanoma are eligible.
- •Patients who have previously had Stage III melanoma at any time are not eligible
- •Recovered from definitive surgery (e.g. no uncontrolled wound
- •infections or indwelling drains).
- •Eastern Cooperative Oncology Group (ECOG) Performance Status of 0-1
- •Other protocol-defined inclusion criteria may apply
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 480
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 120
排除标准
- •Uveal or mucosal melanoma
- •Evidence of metastatic disease including unresectable in-transit metastasis
- •Received any prior adjuvant or neoadjuvant treatment, including but not limited to chemotherapy, checkpoint inhibitors, targeted therapy [e.g., BRAF and/or MEK inhibitors], biologic therapy, vaccine therapy, investigational treatment, or radiotherapy for melanoma
- •Malignant disease, other than that being treated in this study. Exceptions to this exclusion include the following: malignancies that were treated curatively and have not recurred within 2 years prior to study treatment; completely resected basal cell and squamous cell skin cancers and any completely resected carcinoma in situ
- •History or current evidence of cardiovascular risk
- •A history or current evidence/risk of retinal vein occlusion (RVO) or central serous retinopathy
- •Other protocol-defined exclusion criteria may apply
研究者
相似试验
进行中（未招募）
1 期
Study of dabrafenib+trametinib in the Adjuvant treatment of stage III BRAF V600+ melanoma after complete resection to evaluate the impact on pyrexia related outcomesEUCTR2018-000168-27-LVovartis Pharma AG600
尚未招募
Unknown
A phase II, open-label study of dabrafenib plus trametinib in patients with advanced solid tumor having BRAF V600E mutation or clinically actionable BRAF gene alterationsKCT0008405The Catholic University of Korea, Seoul St. Mary's Hospital30
进行中（未招募）
1 期
Study of dabrafenib+trametinib in the Adjuvant treatment of stage III BRAF V600+ melanoma after complete resection to evaluate the impact on pyrexia related outcomesStage III BRAF V600 mutation-positive melanomaMedDRA version: 21.1Level: PTClassification code 10025650Term: Malignant melanomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2018-000168-27-HUovartis Pharma AG600
进行中（未招募）
1 期
Study of dabrafenib+trametinib in the Adjuvant treatment of stage III BRAF V600+ melanoma after complete resection to evaluate the impact on pyrexia related outcomesStage III BRAF V600 mutation-positive melanomaMedDRA version: 21.1Level: PTClassification code 10025650Term: Malignant melanomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2018-000168-27-NOovartis Pharma AG600
进行中（未招募）
1 期
Study of dabrafenib+trametinib in the Adjuvant treatment of stage III BRAF V600+ melanoma after complete resection to evaluate the impact on pyrexia related outcomesStage III BRAF V600 mutation-positive melanomaMedDRA version: 21.1Level: PTClassification code 10025650Term: Malignant melanomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2018-000168-27-LTovartis Pharma AG600